New hope for IBS-D sufferers: ramosetron trial aims to tame diarrhea and pain
NCT ID NCT07574320
First seen May 09, 2026 · Last updated Jun 15, 2026 · Updated 3 times
Summary
This study tests whether the drug ramosetron can reduce belly pain, bloating, and diarrhea in people with diarrhea-predominant irritable bowel syndrome (IBS-D). About 76 adults aged 18–65 will receive either ramosetron or a placebo daily for 4 weeks, along with a low-FODMAP diet and lifestyle advice. Symptoms will be checked using a standard severity score at 4 and 8 weeks to see if the drug provides meaningful relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBS-D (DIARRHEA-PREDOMINANT) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.